Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of “Moderate Buy” from Analysts

Vor Biopharma Inc. (NASDAQ:VOR) has earned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $68.4286.

A number of research analysts recently issued reports on VOR shares. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price on the stock in a research note on Wednesday, September 24th. JPMorgan Chase & Co. lowered their price target on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. HC Wainwright dropped their price objective on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Baird R W upgraded Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 15th. Finally, Wedbush initiated coverage on Vor Biopharma in a report on Tuesday, November 25th. They issued a “neutral” rating on the stock.

Vor Biopharma Stock Performance

NASDAQ:VOR opened at $14.72 on Friday. The company has a 50 day moving average price of $14.88. Vor Biopharma has a 12 month low of $2.62 and a 12 month high of $65.80. The company has a market capitalization of $153.24 million, a price-to-earnings ratio of -0.04 and a beta of 2.08.

Insider Buying and Selling at Vor Biopharma

In related news, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the business’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $30.05, for a total transaction of $349,060.80. Following the transaction, the insider owned 1,167,109 shares of the company’s stock, valued at approximately $35,071,625.45. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Ra Capital Management, L.P. sold 24,579 shares of the company’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $25.12, for a total transaction of $617,424.48. Following the transaction, the director owned 779,652 shares of the company’s stock, valued at approximately $19,584,858.24. The trade was a 3.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 1,674,800 shares of company stock worth $49,516,960. 0.45% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors have recently added to or reduced their stakes in the company. Woodline Partners LP acquired a new position in Vor Biopharma in the 3rd quarter valued at approximately $1,333,000. Polymer Capital Management HK LTD bought a new stake in shares of Vor Biopharma during the third quarter valued at approximately $1,035,000. Millennium Management LLC increased its position in shares of Vor Biopharma by 122.5% during the third quarter. Millennium Management LLC now owns 24,764 shares of the company’s stock valued at $1,207,000 after purchasing an additional 134,764 shares during the period. Fcpm Iii Services B.V. acquired a new position in shares of Vor Biopharma in the third quarter valued at $18,496,000. Finally, Bank of America Corp DE lifted its position in Vor Biopharma by 679.3% in the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after purchasing an additional 4,144 shares during the period. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).